Share Name Share Symbol Market Type Share ISIN Share Description
Sinclair Pharma LSE:SPH London Ordinary Share GB0033856740 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.125p -0.39% 31.875p 31.75p 32.00p 32.25p 31.75p 32.25p 134,466.00 16:35:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 75.9 -8.2 -1.5 - 160.08

Sinclair Pharma Share Discussion Threads

Showing 1626 to 1650 of 1650 messages
Chat Pages: 66  65  64  63  62  61  60  59  58  57  56  55  Older
DateSubjectAuthorDiscuss
28/3/2017
09:53
Cheers once again.
soundbuy
28/3/2017
08:59
I was given the impression following recent conversations with PR companies, that research notes need to be client only and requested by investors directly (SB, hence my email). Perhaps the Hardman notes fall outside of this MIFID 2 type legislation. hTTp://hardmanandco.com/docs/default-source/company-docs/sinclair-pharma-plc-documents/28.03.17-much-more-streamlined.pdf
shroder
27/3/2017
11:08
Interesting appointment RBC RBC also have them as their top pick for M & A activity 2017.....
soundbuy
24/3/2017
19:32
The thing is the announcement was solid and the Company have reduced operating loss and promised to go into profit this year. The market will wait for profits to be achieved before the share price will move North IMHO.
dealit
24/3/2017
19:32
The thing is the announcement was solid and the Company have reduced operating loss and promised to go into profit this year. The market will wait for profits to be achieved before the share price will move North IMHO.
dealit
24/3/2017
17:55
I don't think charting(?) works too well for Aim shares. Strange that Tosca decided to come off from their 29.9%. Aren't they just shooting themselves in the foot? Or are they trying to provide liquidity in the market for some reason?
eggbaconandbubble
24/3/2017
16:36
Trying to evaluate the MA from a chart perspective but I'm a total novice. Looks like we might be potentially about to have a reverse in down trend. Any proper chartist able to confirm?
tini5
24/3/2017
16:01
Thought we may have had a holdings RNS by now but hey ho..........
soundbuy
22/3/2017
08:01
SPH Jefferies International Buy 33.88 34.00 Old PT 55.00 New PT 55.00 Reiterates
soundbuy
21/3/2017
13:53
They'll come a point (possibly within the next 18 months) when Sinclair could well attract predatory interest.Sterling is likely to remain under pressure (making SPH internationally attractive value )as the company moves strongly into profits.Once the hard work has been done and is paying off,who knows.
steeplejack
21/3/2017
13:40
SPH Stifel Buy 33.75 35.00 Old PT 71.00 New PT 71.00 Reiterates
soundbuy
21/3/2017
13:25
Re M&A, first thing that crossed my mind after a second read through later this am. was how a larger Co. like Allergan with a leading medical aesthetics portfolio could strip out costs re sales/marketing/development etc, and bring forward profitability, they even operate R&D centres in the UK, Ireland and France. Interesting times.
soundbuy
21/3/2017
12:39
Equity Development‏ @equity_research 9m9 minutes ago $SPH Sinclair Pharma. Upbeat presentation by CEO (who presented at ED Investor Forum in 2015) at analysts meet @FTIConsulting today.
soundbuy
21/3/2017
10:08
That settlement obviously a downer at the open albeit history now...
soundbuy
21/3/2017
10:05
Cheers.....
soundbuy
21/3/2017
10:03
Sorry, only have the hard copy - there's a couple of revisions but broadly the same from previous note.
shroder
21/3/2017
09:52
PH are house/nomad but would like to see their take on results Gathering a little traction now...
soundbuy
21/3/2017
09:46
Peel Hunt reiterate target price of 68p today.
mfhmfh
21/3/2017
09:42
Any link to that note, would like a gander if possible.
soundbuy
21/3/2017
09:31
It has a lumpy market cap plus no real track record in aesthetics, but as others have pointed out, progress has been solid. Peel has this as their number one pick for 2017 From today's note: "Sinclair remains our top growth pick in UK midcap healthcare."
shroder
21/3/2017
09:16
Understandable market hesitancy but it does look like things might improve substantially over the next couple of years.Given the company's history,'the proof of the pudding will be in the eating'.The next set of figures,should see the company confirming EBITDA profitability and maybe the stock will begin to tick higher.The shares are tightly held afterall and any sustained fresh buying interest should make an impact.I'm fairly confident that the stock should be 40p+ by the year end.
steeplejack
21/3/2017
09:02
'Looking ahead, the Board expects Sinclair to be adjusted EBITDA positive in 2017. Beyond this year, the Board believes that strong core revenue growth augmented by US, Brazil and China launches, combined with operational leverage through rising gross margins and a controlled cost base will position the Company well to deliver superior returns for shareholders". ' Couldn't put it better myself :) Excellent progress to date, well pleased, seem to have hit the ground running since disposal and investment now will reap the rewards later. Jam tomorrow but nature of the business at this stage of development hence the reaction not a surprise, been here before.
soundbuy
21/3/2017
08:53
I don't think you're going to miss out sitting on the sidelines for a few months.
steeplejack
21/3/2017
08:39
sold my holding in two tranches this morning. Growth looks very positive but the sales and marketing spend placed some uncertainty in my mind. It also hit a point of resisitance at 35p and i figured it might just retrace back to support just above 30pish from here. I need to be more convinced on the financial strength before coming back in. woody
woodcutter
21/3/2017
07:56
"Following the non-aesthetics disposal, Sinclair's remaining business had pro-forma 2015 revenues of GBP25 million. Post-restructuring and including the annual contribution to Thermi training costs, Sinclair's breakeven adjusted EBITDA revenue run-rate is approximately GBP47 million. While it was essential for the business to grow quickly in 2016, the business remains forecast to move to a positive adjusted EBITDA in the second half of 2017."Company reducing operating costs and expected to enjoy continued expansion in margins on the back of continued growth in revenue.Once the market decides to focus on prospects for 2018,the shares might begin to perform.For now,everything looks set fair.
steeplejack
Chat Pages: 66  65  64  63  62  61  60  59  58  57  56  55  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20170328 23:34:55